EUCTR2020-000096-21-ATActive, not recruitingPhase 1
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to EnhanceVisualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas - MEN-301
X Development Corp.0 sites100 target enrollmentStarted: July 9, 2020Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.A pre-operative MRI within 30 days of study enrollment documenting a suspected meningioma or suspected recurrence of a meningioma for which a meningioma resection is indicated and has been planned.
- •2. Adult age =18 years
- •3. Patient must have normal organ and bone marrow function and be appropriate surgical canditates per site SOC.
- •4. Patient must have recording of each Parameter as defined below:
- •BilirubinBelow upper limit of normal
- •AST (SGOT)< 2.5 X institutional upper limit of normal
- •ALT (SGPT)< 2.5 X institutional upper limit of normal
- •CreatinineBelow upper limit of normal
- •Creatinine clearance >60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
- •5. The Patient/patient´s legally authorized representative (LAR) will have to demonstrate the ability to understand, informed consent, and the willingness and ability to sign a written informed consent document. The study consent documents will be prepared in English and German and Spanish. Translation for non-English, non-German, or non-Spanish speaking participants will be provided as appropriate by Institution.
- •6.WOCBP and men participating must agree to use highly effective forms of contraception, and men must also agree not to donate sperm for the duration of treatment, and for at least 42 days after the one time use of the study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
Exclusion Criteria
- •1. History of allergic reactions attributed to compounds of similar chemical/biologic composition to Gleolan.
- •2. Known or documented personal or family history of porphyria.
- •3. Uncontrolled concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness
- •4. Patient has had a meningioma resection or radiation treatment within 90 days of informed consent
- •5. Social or medical situations that would limit compliance with study requirements (e.g. ability to travel for follow-up or inability to obtain appropriate pre-op MRI (e.g. cardiac pacemaker)
- •6. Women who are pregnant or plan to become pregnant during study participation.
- •7. Prior history of gastrointestinal perforation, diverticulitis, and or/peptic ulcer disease.
- •8. Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment or within 5 plasma half-life of the preceding study drug, whatever is longer.
- •9. Simultaneous use of other potentially phototoxic substances (St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period
- •10. Unwillingness by patient to sign consent or return for subsequent visits following surgery
- •11. Any condition that in the opinion of the Investigator would exculde the patient as a viable candidate for this study
- •12. Patient undergoing planned embolization prior to meningioma resection that is separate from the meningioma resection procedure itself.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study on how effective Gleolan is as a maker for tumor cells during brain surgeryMedDRA version: 21.1Level: PTClassification code 10027191Term: MeningiomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MeningiomaEUCTR2020-000096-21-DEX Development Corp.100
Completed
Phase 3
Gleolan for Visualization of Newly Diagnosed or Recurrent MeningiomaMeningiomaNCT04305470NX Development Corp108
Recruiting
Phase 3
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)Ovarian CancerNCT05804370NX Development Corp170
Active, not recruiting
Phase 1
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)Tuberous Sclerosis Complex (TSC) related epilepsyMedDRA version: 20.0Level: LLTClassification code: 10032062Term: Other forms of epilepsy with intractable epilepsy Class: 10029205CTIS2022-503067-15-00Marinus Pharmaceuticals Inc.166
Withdrawn
Phase 3
Study to Assess Acute Vasodilation Response of Inhaled Nitric OxidePulmonary Arterial HypertensionNCT02436512Geno LLC